Pathstone Holdings LLC Has $8.69 Million Position in GSK plc (NYSE:GSK)

Pathstone Holdings LLC lifted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 256,715 shares of the pharmaceutical company's stock after acquiring an additional 10,101 shares during the quarter. Pathstone Holdings LLC's holdings in GSK were worth $8,686,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Indiana Trust & Investment Management Co boosted its position in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK in the 4th quarter worth approximately $26,000. Sierra Ocean LLC acquired a new stake in shares of GSK in the 4th quarter valued at $32,000. Parkside Financial Bank & Trust boosted its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares during the last quarter. Finally, Golden State Wealth Management LLC acquired a new position in shares of GSK during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

GSK has been the topic of several recent research reports. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Stock Performance

Shares of NYSE:GSK traded up $0.11 during trading on Thursday, reaching $38.65. 1,664,969 shares of the stock were exchanged, compared to its average volume of 4,826,088. The firm has a market cap of $79.74 billion, a PE ratio of 24.31, a PEG ratio of 1.12 and a beta of 0.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.80. The stock has a 50-day moving average price of $37.33 and a 200-day moving average price of $36.00.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.43 EPS. Research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.36%. GSK's payout ratio is 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.